Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.6K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.6K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensive care under uncertainty: a qualitative study of how older patients and their relatives wish to contribute to decision-making.

European geriatric medicine·2026
Same author

HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Differential assembly of mouse and human tumor microenvironments.

Nature immunology·2026
Same author

Clinical Validation of the Belay Ascentâ„¢ Test to Report on Chromosomal Arm-Level Aneuploidy and Gene-Level Copy Number Variants in Cerebrospinal Fluid Using Low-Pass Whole-Genome Sequencing.

Cancers·2026
Same author

Exploring the Lack of Concordance between the Preferred and Actual Approach to Colorectal Cancer Screening in Older Adults: A Qualitative Study.

Medical decision making : an international journal of the Society for Medical Decision Making·2026
Same journal

Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study.

JCO precision oncology·2026
Same journal

Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.

JCO precision oncology·2026
Same journal

Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.

JCO precision oncology·2026
Same journal

Multimodal Spatiotemporal Signature Integrating Pathomics and Longitudinal Magnetic Resonance Imaging Predicts Response to Neoadjuvant Therapy and Prognosis in Rectal Cancer.

JCO precision oncology·2026
Same journal

Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

JCO precision oncology·2026
Same journal

Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis.

JCO precision oncology·2026
See all related articles

Related Experiment Video

Updated: Jul 31, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.4K

The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State.

Jens Rueter1, Eric C Anderson2,3, Leah C Graham1

  • 1The Jackson Laboratory, Augusta, ME.

JCO Precision Oncology
|May 10, 2023
PubMed
Summary
This summary is machine-generated.

The Maine Cancer Genomics Initiative successfully implemented genomic tumor testing (GTT) and genomic tumor boards (GTBs) in rural Maine. This initiative expanded precision oncology access for cancer patients, overcoming geographical and provider barriers.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.1K

Related Experiment Videos

Last Updated: Jul 31, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.4K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.9K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.1K

Area of Science:

  • Oncology
  • Genomics
  • Health Services Research

Background:

  • Rural cancer patients face barriers to genomic tumor testing (GTT).
  • The Maine Cancer Genomics Initiative (MCGI) addressed these barriers in a large, rural state.
  • Limited access to precision oncology impacts cancer care delivery.

Purpose of the Study:

  • To describe the successful implementation of the MCGI.
  • To detail the provision of genomic tumor boards (GTBs), clinician education, and GTT access.
  • To assess the impact of the initiative on precision oncology adoption in rural practices.

Main Methods:

  • A community-inclusive, hub-and-spoke model was employed.
  • Key components included a centralized GTB program, modular online education, and free GTT.
  • Implementation timelines, participation metrics, and survey data were collected.

Main Results:

  • The MCGI engaged all 19 oncology practices in Maine within 18 months.
  • Seventy-nine physicians representing 100% of practicing oncologists enrolled.
  • 1610 patients were enrolled, with 515 cases discussed in 196 GTBs by 73% of clinicians.

Conclusions:

  • The MCGI successfully engaged disparate cancer care practices in a precision oncology program.
  • A hub-and-spoke model facilitated access to GTT, education, and GTBs.
  • The initiative narrowed the implementation gap for precision oncology in a rural state.